Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088709 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
A Phase 2 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03088709 is a Phase 2 study that was terminated before completion, run by Loyola University. The registered enrollment target is 5 participants.
The verdict
NCT03088709, a Phase 2 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for SCT. Alternative donor sources include matched unrelated donor utilizing the donor registry, cord blood transplant and mismatched donor transplant. A human leukocyte antigen (HLA)-haploidentical donor is one who shares, by common inheritance, exactly one HLA haplotype with the recipient, and includes the biologic parents, biologic children and full or half siblings. There is strong body of evidence supporting the use of haplo-SCT in patient who lack a matched sibling or unrelated donor with high rates of successful engraftment, effective Graft Versus Host Disease (GVHD) control and favorable outcomes comparative to those seen using other allograft sources, including HLA-matched sibling SCT. Furthermore, it provides a cost-efficient donor option in a timely manner especially for patients who need to proceed quickly to transplant due to concern of disease relapse/progression.
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- OTHER Haploidentical Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088709
The ClinicalTrials.gov registry entry for NCT03088709 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03088709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03088709 about?
NCT03088709 is a clinical study titled "Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide". Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for SCT. Alternative donor sources include matched unrelated donor utilizi...
What is the current status of trial NCT03088709?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-01-18. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT03088709?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Haploidentical Stem Cell Transplantation (OTHER).
Who is sponsoring clinical trial NCT03088709?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.